Corporate Update Simon Hubbert, CEO Bill Kullback, CFO June, 2015
|
|
- Delilah Flynn
- 6 years ago
- Views:
Transcription
1 (Nasdaq:EVAR) Corporate Update Simon Hubbert, CEO Bill Kullback, CFO June, 2015
2 Safe Harbor This presentation contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements are based on management s current expectations, but are subject to risks and uncertainties that could cause actual results to differ materially from either historical or anticipated results depending on a variety of factors. All statements contained in this presentation that do not describe historical facts may constitute forward-looking statements. Statements that address activities, events or developments that we expect or anticipate may occur in the future, including such things as our outlook, future capital expenditures, changes to the composition or level of our revenues, cash flow and liquidity, compound annual growth rates (CAGR), business strategies, competitive strengths, goals, the benefits of new initiatives, growth of our business and operations, plans and references to future successes, are forward-looking statements. Also, when we use the words such as anticipate, believe, estimate, expect, intend, plan, probably, or similar expressions, we are making forward-looking statements. The following factors, among others, could cause actual results to differ from those set forth in the forward-looking statements: risks and uncertainties relating to adverse changes in conditions in the global economy and volatility in the capital markets, the development and commercialization of the Company s products, the Company s distribution network, the cost and pricing of the Company s products, physician education, manufacturing, competition, dependence on collaborative partners and key suppliers, capital spending and funding policies, changes in governmental regulations, intellectual property rights, litigation, and exposure to foreign currency fluctuations and other risk factors discussed from time to time in the Company s filings with the Securities and Exchange Commission (the SEC ). These and other factors are identified and described in more detail in the Company s filings with the SEC, including, without limitation, the Company s recent Annual Report on Form 20-F and the Company s other reports on Form 6-K. All forward-looking statements in this presentation are made as of the date of this presentation. We do not undertake, and expressly disclaim, any intent or duty to update these forward-looking statements whether as a result of new information, future events or changes in expectations, other than as required by law. This presentation is for information purposes only and does not constitute an offer of, or a solicitation to purchase or subscribe for, any securities. You should make your own independent examination of us and consult your own independent counsel, business advisors, tax advisors, investment advisors or other authorized advisors as to the legal, business, tax, investment or any other matters pertaining to us or our securities. 2
3 Lombard Medical at a Glance An innovative vascular device company A global, commercial stage medical technology company Headquarters in Irvine, CA, manufacturing in Oxfordshire, UK Focused on the $1.6B abdominal aortic aneurysm ( AAA ) repair market Aorfix: The only globally approved AAA stent-graft for aortic neck angles up to 90 degrees Commercially focused in US, Europe, Japan FDA approved, formal launch Nov 2013 Regulatory approval in Japan, launch in Sept 2014 NASDAQ IPO on Apr. 25, 2014 (ticker: EVAR) raised $55M Objective To offer Endovascular AAA repair to more patients than our competitors 3
4 $Billions EVAR Market is Attractive with Strong Growth Global addressable market of $1.6B growing at a CAGR of 6% annually Overview of AAA ~500,000 patients diagnosed annually Untreated AAA can rupture and cause death Current AAA treatment Minimally invasive EVAR = 75% of procedures Open repair surgery = 25% of procedures EVAR Market EVAR market drivers Aging patient population Increase in AAA screening Better outcome vs. surgery $1.9 Billion by WW market = $1.6B 1 6% CAGR growth annually 1 EVAR is growing vs. open surgical repair Lower mortality rate Lower morbidity/fewer complications Shorter hospital stay (approx. 3 days vs. 9 days) $1.4 $1.5 $1.6 $1.7 $1.8 $1.9 Shorter recovery period (2 weeks vs. 12 weeks) Tortuous Anatomy is a significant issue 20% of AAA patients have neck angles >60 degrees 10% of AAA patients have tortuous iliac vessels Medtech Ventures: Aortic Intervention Market (2014)
5 Flexible halo Design Offers Unrivalled Flexibility Competitors' Z type metallic ring designs are more rigid, may kink in tortuous anatomy increasing re-interventions and poor clinical outcomes 5
6 Unique Design to Address Tortuous Anatomy Aorfix can provide better outcomes for patients with tortuous vascular anatomy Proprietary halo Stent Technology featuring helical and circular design promotes flexibility Before procedure 12 months after procedure 6 Source: Images courtesy of Musgrove Park Hospital, Taunton
7 Broadest Global Indication Company AAA Stent-Graft Max Approved US Neck Angle Indication Lombard Aorfix 90 Medtronic Endurant 60 Cook Zenith 60 Gore Excluder 60 Endologix Powerlink 60 TriVascular Ovation 60 Potential to expand physicians on-label practice by ~20% 7
8 Lombard is Focused on Three Key Markets Global EVAR Market Landscape United States Europe Japan ~ $714M 1 ~ $477M 2 ~ $158M 2 13 th leading cause of death in US and the 10 th leading cause of death in US men aged 65 years and older Each year, 200,000 patients are diagnosed with AAA High EVAR volumes and higher selling price Market was estimated to be $477M in 2014; growing at an average growth rate of 6% Germany and the United Kingdom are two of the three largest and the most receptive EVAR markets 2nd largest standalone EVAR market in the world growing at an average rate of 18% Highly developed and lucrative market with high barriers to entry ~400 physicians at 200 clinics performing EVAR and it is estimated that approximately 55% of Japanese AAA patients are treated using this method 8 1 idata Research Inc.: US Market for Peripheral Vascular Devices and Accessories (2013) 2 Medtech Ventures: Aortic Intervention Market (2014)
9 US Commercial Strategy US is the largest AAA market valued at an estimated $714M in 2014 Aorfix FDA approved - full commercial launch November 2013 Build out experienced sales force to 35 in mid-2015 Recruiting experienced EVAR reps or those with strong endovascular experience Equipped with most advanced field training tools Aorfix cases completed in almost 150 US centers since launch using least invasive technique across all neck angles: ~50% below 60 degree neck angulation More than half performed percutaneously 9
10 Japanese Commercial Strategy Japanese Market Dynamics World s second largest AAA market ~8,000 AAA procedures in 2014 Well reimbursed ~$14,000 1 Launch of Aorfix in Japan Partnering with Medico s Hirata Medico s Hirata has significant experience in EVAR and a direct sales force trained in the Japanese AAA market due to a prior relationship with another AAA stent-graft company Unique regulatory approval for Aorfix to treat angulation 90 degrees granted in August 2014 Formal launch in September Strong start, tracking toward 5% market share in Q2/ Approval of latest Aorflex delivery system received in Q Medtech Ventures: Aortic Intervention Market (2014)
11 Well Established European Union Strategy Four main EU markets are: UK, Germany, Spain and Italy Direct-markets: UK and Germany Key distribution markets: Spain and Italy Primarily utilize country-specific distributors for smaller EU countries Aorfix high angle approval in % UK market share in 3 years U.K. Direct Distributor Direct-markets with sales team of 10 Expect to increase sales force in Germany Germany Western Europe direct market sales increased 14% in 2014 to $3.4M Spain Spain and Italy are supported by a sales manager in each country Italy 11
12 Lombard Revenue Contribution by Geography $M $M Q Q Q US Market W Europe Direct Markets 2015 Projection ($18-20M) JP Market ROW Distributor Markets JP Market ROW Distributor Markets US Market W Europe Direct Markets Accelerating Revenue from US and Japan Launch 12
13 Platform Technology with Strong Development Pipeline Aorfix Plus size range extension FDA approved to 36mm Ability to treat patients with larger anatomies Allows treatment of up to 10% more patients with Aorfix US launch of 34mm stent graft in Q Next-generation delivery systems Lower profile design treat patients with narrow access vessels Exchange sheath reduce vessel trauma Intuitive & compact ease of use Regulatory submission of next generation IntelliFlex LP system anticipated 2H 2015 with expected approval within 90 days of submission Thoracic stent-graft 13 New Product Development Potential to develop technology to expand indications within endovascular surgery To treat thoracic aneurysms (TEVAR) To treat complex short neck anatomy (FEVAR)
14 Thoracic EVAR (TEVAR) Market Aorfix technology can be applied to TEVAR segment US market forecasted to grow by 79% from TEVAR Stent Business Opportunity Aorfix flexibility should offer significant advantages over competitors in thoracic arch Market Size Units $450 38,395 $M $287 23, E 2018E 2013E 2018E EU US 14 idata Research Inc.: US Market for Peripheral Vascular Devices and Accessories (2013)
15 Fenestrated EVAR (FEVAR) Market FEVAR Business Opportunity Aorfix technology has the potential to address the FEVAR segment Aorfix technology may offer significant advantages over competitors Compliant construction allows fenestrations to have mobility and reduces No-Go areas for fenestration Off-the-shelf devices could treat many more anatomies Flexible construction eases angulation restrictions placed on existing commercial FEVAR IFUs Fenestrated and branched aortic endografts in 2014 totaled $50M in global sales and is expected to grow 1 Several studies have shown that the average incidence of short necks (<10mm) is at least 20% of the $1.4B aortic endograft market 2 $280M market opportunity which is currently underserved 15 1.Aortic Endografts Market 2015 Report 2.Company Estimates based on currently available published studies
16 Financial Highlights Q and Guidance Total 2015 first quarter Aorfix revenue grew 66% to $3.4M compared to revenue of $2.1M in the first quarter of US Aorfix revenue grew to $1.1M in the first quarter of 2015, up 125% from $0.5M in the first quarter of Gross margin for the 2015 first quarter was 46% compared to 34% for the prior year period. In April, the Company entered into a $26M secured term loan facility with Oxford Finance LLC. Lombard Medical received $11M in proceeds at the loan closing on April 24 with additional funds becoming available upon achievement of near-term revenue milestones. Cash at March 31, 2015 was $45.1M. FY 2015 Guidance Revenues of $18M - $20M Procedure numbers to more than double in four key markets (US, Japan, Germany, UK) 16
17 Conclusion: A Differentiated Growth Opportunity in AAA Large Addressable Market Opportunity Focused on attractive $1.6B global EVAR market forecast to grow at 6% CAGR Approved and Highly Differentiated Product Aorfix is the only globally-approved endovascular stent-graft for neck angulations up to 90 Platform technology can expand into new indications and areas Strong Supporting Clinical Data Strong clinical data from US IDE study (PYTHAGORAS) Strong Financial Profile Strong Aorfix revenue growth Public market track record and $45.1M in cash (3/31/15) Clear Strategy for Growth Geography expand US sales force and accelerate roll out, launch in Japan, expand presence in Europe and Asia Product Enhanced Aorfix delivery systems; thoracic stent graft Experienced Management Team Highly experienced management team with significant medtech experience 17
NASDAQ: ELGX December Innovation that Empowers
NASDAQ: ELGX www.endologix.com December 2014 Innovation that Empowers Safe Harbor This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act
More informationView Report Details. Global Aortic Aneurysm Market: Trends and Opportunities ( )
View Report Details Global Aortic Aneurysm Market: Trends and Opportunities (2014-2019) View Report Details Scope of the Report The report titled Global Aortic Aneurysm Market: Trends and Opportunities
More informationST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015
ST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015 1 FORWARD LOOKING STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation
More information34 th Annual J.P. Morgan Healthcare Conference
JANUARY 2016 34 th Annual J.P. Morgan Healthcare Conference [ 1 ] Forward Looking Statements SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS In addition to historical information, this presentation contains
More informationCurrent Status of EVAR for Infrarenal AAA. 31 st Annual Florida Vascular Society. PENN Surgery
Current Status of EVAR for Infrarenal AAA 31 st Annual Florida Vascular Society PENN Surgery No Disclosures Stent Grafts Design Related Differences What really matters? Modular Unibody Supported Unsupported
More informationOvation. Sean Lyden, MD Department Chair, Vascular Surgery Cleveland Clinic
Ovation Sean Lyden, MD Department Chair, Vascular Surgery Cleveland Clinic Disclosure Statement of Financial Interest Within the past 12 months, I or my spouse/partner have had a financial interest/arrangement
More informationAccess More Patients. Customize Each Seal.
Access More. Customize Each Seal. The Least Invasive Path Towards Proven Patency ULTRA LOW PROFILE TO EASE ADVANCEMENT The flexible, ultra-low 12F ID Ovation ix delivery system enables you to navigate
More informationJanuary 2017 Investor Presentation. confidently live life with ease
January 2017 Investor Presentation confidently live life with ease Forward-Looking Statements This presentation contains certain forward-looking statements that involve risks and uncertainties that could
More informationSmall-Cap Research. Lombard Medical (EVAR-NASDAQ) EVAR: Exploiting High Neck Angle Stent- Graft Market. Initiating Coverage at Outperform OUTLOOK
Small-Cap Research March 24, 2015 Brian Marckx, CFA bmarckx@zacks.com Ph (312) 265-9474 scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Lombard Medical (EVAR-NASDAQ) EVAR: Exploiting High Neck Angle
More informationBuilding a Premier Oncology Biotech
Corporate Deck Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO November 2018 Forward-Looking Statements All of the statements in this presentation that are not statements of historical
More informationJanuary 30, 2018 Dow Wilson President and Chief Executive Officer
Acquisition of SIRTeX January 30, 2018 Dow Wilson President and Chief Executive Officer This presentation is intended exclusively for investors. It is not intended for use in Sales or Marketing. Forward-Looking
More informationAcquisition of Novartis Influenza Vaccines Business. 27 th October 2014
1 Acquisition of Novartis Influenza Vaccines Business 27 th October 2014 2 Legal Notice Forward looking statements The materials in this presentation speak only as of the date of these materials, and include
More informationREFERENCE CODE GDME1117CFR PUBLICAT ION DATE OCTOBER 2014 AORTIC STENT GRAFTS EU ANALYSIS AND MARKET FORECASTS
REFERENCE CODE GDME1117CFR PUBLICAT ION DATE OCTOBER 2014 AORTIC STENT GRAFTS Executive Summary Table below provides the key metrics for aortic stent grafts in the 5EU (France, Germany, Italy, Spain, and
More informationLOWERING THE PROFILE RAISING THE BAR
LOWERING THE PROFILE RAISING THE BAR INNOVATIVE LOW PROFILE. ADVANCED CLINICAL PERFORMANCE. The AFX TM Endovascular AAA System integrates anatomical fixation with an advanced delivery system and graft
More informationAnnual Shareholders Meeting
Annual Shareholders Meeting February 8, 2018 Dow R. Wilson, President and Chief Executive Officer Forward-Looking Statements Except for historical information, this presentation contains forward-looking
More informationAsia-Pacific Bariatric Surgery Devices Market Outlook to 2020
Asia-Pacific Bariatric Surgery Devices Market Outlook to 2020 Reference Code: GDMECR0195DB Publication Date: July 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 4 1.2 List
More informationGenomic Health. Kim Popovits, Chairman, CEO and President
Genomic Health Kim Popovits, Chairman, CEO and President Safe Harbor Statement Various remarks that we make in this presentation that are not historical, including those about our future financial and
More informationAsia-Pacific Endoscopic Retrograde Cholangiopancreatography (ERCP) Procedures Outlook to 2020
Asia-Pacific Endoscopic Retrograde Cholangiopancreatography (ERCP) Reference Code: GDMECR0107PDB Publication Date: July 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 3
More informationSlide 1. Financial update and closing remarks. Jesper Brandgaard EVP and CFO. RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A
Slide 1 Financial update and closing remarks Jesper Brandgaard EVP and CFO RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A Slide 2 Forward-looking statements Novo Nordisk s reports filed with or
More informationEvolution of gender-related differences in outcome of EVAR
Evolution of gender-related differences in outcome of EVAR Erik Debing Department of Vascular Surgery University Hospital Brussels Disclosure Speaker name: ERIK DEBING... I have the following potential
More informationBuilding a Premier Oncology Biotech
Wells Fargo Securities Healthcare Conference Building a Premier Oncology Biotech Dr. Helen Torley, President and CEO September 2018 Forward-Looking Statements All of the statements in this presentation
More informationBRIC Transurethral Resection of the Prostate (TURP) Procedures Outlook to 2020
BRIC Transurethral Resection of the Prostate (TURP) Procedures Outlook Reference Code: GDMECR0130PDB Publication Date: July 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables...
More informationSolutions For The Aging Spine
Solutions For The Aging Spine NASDAQ: ATEC February 2009 www.alphatecspine.com Slide 0 5818 El Camino Real, Carlsbad, CA 92008 www.alphatecspine.com Forward Looking Statements This presentation and our
More informationEU5 Bariatric Surgery Procedures Outlook to 2020
EU5 Bariatric Surgery Procedures Outlook to 2020 Reference Code: GDMECR0089PDB Publication Date: July 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 3 1.2 List of Figures...
More informationSlide 1. Investor presentation. London 5 February 2019
Slide Investor presentation London 5 February 209 Slide 2 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including this presentation
More informationUniversal Biosensors, Inc.
Universal Biosensors, Inc. ARBN 121 559 993 Buchan Three Tickers Presentation 18 th September 2013 1 Important Disclaimer This presentation is intended to provide a general outline only and is not intended
More information37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE
37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE January 2019 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as
More informationOBALON THERAPEUTICS, INC. (OBLN) The first and only FDA-approved swallowable, gas-filled intragastric balloon for weight loss
OBALON THERAPEUTICS, INC. (OBLN) The first and only FDA-approved swallowable, gas-filled intragastric balloon for weight loss Forward looking statements Except for statements of historical fact, information
More informationChallenges with Complex Anatomies Advancing Care in Endovascular Aortic Treatment
Challenges with Complex Anatomies Advancing Care in Endovascular Aortic Treatment Robert Y. Rhee, MD Chief, Vascular and Endovascular Surgery Director, Aortic Center Maimonides Medical Center Brooklyn,
More informationConflicts of Interest. When and Why Complex EVAR in Tx of juxta/suprarenal AAA? Summary. Infrarenal EVAR for short necks 2y postop
When and Why Complex EVAR in Tx of juxta/suprarenal AAA? Tim Resch MD Vascular Center Skane University Hospital Conflicts of Interest COOK Medical - Consulting, Speakers Bureau, IP, Research support Medtronic
More informationChina Cranio Maxillofacial Fixation (CMF) Market Outlook to 2020
China Cranio Maxillofacial Fixation (CMF) Market Outlook to 2020 Reference Code: GDMECC0079DB Publication Date: March 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 4 1.2
More informationForward-looking Statement Disclaimer
Forward-looking Statement Disclaimer This presentation may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to
More informationBuilding a Premier Oncology Biotech
Building a Premier Oncology Biotech August 208 Forward-Looking Statements All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements within
More informationA New EVAR Device for Infrarenal AAAs
A New EVAR Device for Infrarenal AAAs Peter Nelson, MD, MS Assistant Professor of Surgery MM0203 Rev. 01 Current U.S. EVAR Devices Anatomical Fixation Proximal Fixation Powerlink - Endologix Excluder WL
More informationVisionary Private Equity Group is Pleased to Announce its Investment in MEDITE Cancer Diagnostics
Dear VPEG Limited Partner, We hope this investor update finds you well. We're pleased to share with you an important update below on the following: Visionary Private Equity Group is Pleased to Announce
More informationSlide 1. International Operations update. Mike Doustdar EVP International Operations. YASMIN FIEDLER, Germany Yasmin has type 1 diabetes
Slide 1 International Operations update Mike Doustdar EVP International Operations YASMIN FIEDLER, Germany Yasmin has type 1 diabetes Slide 2 Forward-looking statements Novo Nordisk s reports filed with
More informationValue creation through profitable growth Danske Bank Winter Seminar 2017, Copenhagen Lars Rasmussen, President & CEO
Value creation through profitable growth Danske Bank Winter Seminar 2017, Copenhagen Lars Rasmussen, President & CEO Forward-looking statements The forward-looking statements contained in this presentation,
More informationTalent Abdominal Stent Graft
Talent Abdominal with THE Xcelerant Hydro Delivery System Expanding the Indications for EVAR Treat More Patients Short Necks The Talent Abdominal is the only FDA-approved device for proximal aortic neck
More informationAsia-Pacific Electrophysiology Market Outlook to 2020
Asia-Pacific Electrophysiology Market Outlook to 2020 Reference Code: GDMECR0114DB Publication Date: May 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 5 1.2 List of Figures...
More informationForward-Looking Statements
Investor Presentation May 2012 Forward-Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended.
More informationLess Invasive EVAR Transitioning to a Fast-Track Protocol
Less Invasive EVAR Transitioning to a Fast-Track Protocol Mario Lachat, MD University of Zurich Department of Cardiovascular Surgery Switzerland LINC 2015 1 Disclosure Speaker name: Mario Lachat, MD I
More informationOptimizing Accuracy of Aortic Stent Grafts in Short Necks
Optimizing Accuracy of Aortic Stent Grafts in Short Necks Venkatesh Ramaiah, MD, FACS Medical Director Arizona Heart Hospital Director Peripheral Vascular and Endovascular Research Arizona Heart Institute
More informationRevolutionizing how advanced heart disease is treated. Alexei Marko, CEO Chris Clark, CFO November 2014
Revolutionizing how advanced heart disease is treated Alexei Marko, CEO Chris Clark, CFO November 2014 Forward-Looking Statements Statements contained herein that are not based on historical or current
More informationTSX Venture: RVV OTCQB: RVVTF
TSX Venture: RVV OTCQB: RVVTF The image part with relationship ID rid3 was not found in the file. 2017 Annual General and Special Meeting of Shareholders December 19, 2017 Revive Therapeutics Ltd. Office:
More informationTHE THE MORE MORE NATURAL APPROACH TO OPTIMAL FIT
THE THE MORE MORE NATURAL APPROACH Natural Approach TO Optimal Fit TO OPTIMAL FIT Conformability without Compromise THE STANDARD IN Conformability AND Designed for flexibility and conformability in tortuous
More informationAbdominal and thoracic aneurysm repair
Abdominal and thoracic aneurysm repair William A. Gray MD Director, Endovascular Intervention Cardiovascular Research Foundation Columbia University Medical Center Abdominal Aortic Aneurysm Endografts
More informationMyriad Genetics Corporate Presentation 06/13/2018
Myriad Genetics Corporate Presentation 06/13/2018 Copyright 2016 2018 Myriad Genetics, Inc., all rights reserved. www.myriad.com. 1 Forward Looking Statements Some of the information presented here today
More informationClovis Oncology Announces Q Operating Results and Corporate Update. November 3, :05 PM ET
Clovis Oncology Announces Q3 2016 Operating Results and Corporate Update November 3, 2016 4:05 PM ET Rucaparib New Drug Application (NDA) accepted for Priority Review in the treatment of advanced BRCA-mutant
More informationThe evolution. AORFIX AAA Stent Graft now with the new AORFLEX Delivery System
The evolution of AORFIX AORFIX AAA Stent Graft now with the new AORFLEX Delivery System The confident choice for the right angles AORFIX the only AAA stent graft approved for all angulations from 0 90,
More informationRobotic Spine Surgery [TASE]: MZOR
Robotic Spine Surgery [TASE]: MZOR Nov. 2012 Forward Looking Statements Any forecast and/or forecasting statement, included in this presentation, is based on the Management's assessment at its discretion.
More informationH. LUNDBECK A/S. Teleconference. 10 August PM CET. Financial results Second quarter 2011
H. LUNDBECK A/S Teleconference 10 August 2011-2PM CET Financial results Second quarter 2011 Company disclaimer This presentation contains forward-looking statements that provide our expectations or forecasts
More informationVITROLIFE AB (PUBL) Pareto Securities Health Care Conference
VITROLIFE AB (PUBL) Pareto Securities Health Care Conference 2018-09-06 1 2 10 15 % OF ALL COUPLES IN FERTILE AGE SUFFER FROM FERTILITY PROBLEMS LEADING COMPANY IN MEDICAL DEVICES FOR ASSISTED REPRODUCTION
More informationDARA Reports Year-End 2012 Financial Results
April 1, 2013 DARA Reports Year-End 2012 Financial Results Company Provides a Commercial Portfolio and Development Pipeline Business Update RALEIGH, NC -- (MARKETWIRE) -- 04/01/13 -- DARA BioSciences,
More informationDegeneration of the Neck Post Implementation - a New Era of AAA Stent
Degeneration of the Neck Post Implementation - a New Era of AAA Stent New Mexico Heart Institute Albuquerque, New Mexico USA - Gore Current FDA-Approved EVAR Devices Sealing Mechanism Endologix Lombard
More informationOral semaglutide and production expansion. Henrik Wulff EVP Product Supply. Peter Kristensen SVP Global Development
YASMIN FIEDLER Germany Yasmin has type 1 diabetes Slide 1 Oral semaglutide and production expansion Henrik Wulff EVP Product Supply Peter Kristensen SVP Global Development Slide 2 Forward-looking statements
More informationInvestor Presentation June 2012 NASDAQ: CEMI
Investor Presentation June 2012 NASDAQ: CEMI Forward-Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act
More informationDesigning a Smoke-Free Future
Designing a Smoke-Free Future Morgan Stanley Global Consumer & Retail Conference New York, November 14, 2017 Jacek Olczak Chief Financial Officer Martin King President, Asia Region Forward-Looking and
More informationAllergy Therapeutics. Corporate Presentation. Proactive Investors 28th January 2016 Ian Postlethwaite, Finance Director
Allergy Therapeutics Corporate Presentation January 2016 Introduction We treat people with Allergic disorders Focused on the moderate to severe patients Providing treatments that cure the disease, not
More informationCowen Investor Conference March confidently live life with ease
Cowen Investor Conference March 2018 confidently live life with ease Forward-Looking Statements This presentation contains certain forward-looking statements that involve risks and uncertainties that could
More informationCorporate Presentation
Corporate Presentation January 2019 2018 Chembio. All Rights Reserved. # 2019 Chembio. All Rights Reserved. Page 1 Safe Harbor Statement Statements contained herein that are not historical facts are forward-looking
More informationconfidently live life with ease Management Presentation
confidently live life with ease Management Presentation 1 Forward-Looking Statements This presentation contains certain forward-looking statements that involve risks and uncertainties that could cause
More informationMexico Ostomy Drainage Bags Market Outlook to 2020
Mexico Ostomy Drainage Bags Market Outlook to 2020 Reference Code: GDMECC0990DB Publication Date: October 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 4 1.2 List of Figures...
More informationAnnual Stockholder Meeting May 30, confidently live life with ease
Annual Stockholder Meeting May 30, 2018 confidently live life with ease Forward-Looking Statements This presentation contains certain forward-looking statements that involve risks and uncertainties that
More information2006 Annual Report. Anastomosis Made Simple
2006 Annual Report R Anastomosis Made Simple Cardica designs and manufactures proprietary automated anastomosis systems used by surgeons to perform rapid, reliable and consistent connections, or anastomoses,
More informationCurrent Status of Abdominal Aortic Stent Grafts. John R. Laird Professor of Medicine Director of the Vascular Center UC Davis Medical Center
Current Status of Abdominal Aortic Stent Grafts John R. Laird Professor of Medicine Director of the Vascular Center UC Davis Medical Center Autumn Greetings Disclosure Statement of Financial Interest Within
More information14F OD Ovation Abdominal Stent Graft System
14F OD Ovation Abdominal Stent Graft System 2 Year Results from the European Study Dierk Scheinert, MD Center for Vascular Medicine Angiology and Vascular Surgery Park Hospital Leipzig, Germany Disclosure
More informationCorporate Presentation Fourth Quarter 2017
Corporate Presentation Fourth Quarter 2017 November 2017 1 Safe harbor statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as
More informationA world leader in allergy immunotherapy
A world leader in allergy immunotherapy Investor Relations presentation June 2017 1 I Investor Relations presentation I June 2017 ALK: Towards redefining treatment of severe allergies The commercial leader
More informationPhotocure ASA Executing the Strategy
Photocure ASA Executing the Strategy NOVEMBER 2012 ERIK DAHL, CFO KATHLEEN DEARDORFF, COO Disclaimer The information included in this Presentation contains certain forward-looking statements that address
More informationSlide 1. Welcome and introduction. Lars Rebien Sørensen President & CEO
Slide 1 Lars Rebien Sørensen President & CEO Slide 2 Capital Markets Day 2015 Slide 3 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities and Exchange Commission
More informationHistory of the Powerlink System Design and Clinical Results. Edward B. Diethrich Arizona Heart Hospital Phoenix, AZ
History of the Powerlink System Design and Clinical Results Edward B. Diethrich Arizona Heart Hospital Phoenix, AZ Powerlink System: Unibody-Bifurcated Design Long Main Body Low-Porosity Proprietary eptfe
More informationNeovasc Inc. Alexei Marko, CEO. January 2012 OneMedForum
Neovasc Inc. Alexei Marko, CEO January 2012 OneMedForum 2 Forward-Looking Statements Statements contained herein that are not based on historical or current fact, including without limitation statements
More informationVITROLIFE AB (PUBL) NORDEA Small & Mid Cap Seminar
VITROLIFE AB (PUBL) NORDEA Small & Mid Cap Seminar 2018-08-16 1 2 10 15 % OF ALL COUPLES IN FERTILE AGE SUFFER FROM FERTILITY PROBLEMS LEADING COMPANY IN MEDICAL DEVICES FOR ASSISTED REPRODUCTION A Swedish
More informationTamsulosin Hydrochloride 0.4 mg Capsule
Tamsulosin Hydrochloride 0.4 mg Capsule, Tamsulosin Hydrochloride 0.4 mg Capsule India, Tamsulosin Hydrochloride 0.4 mg Capsule manufacturers India, side effects Tamsulosin Hydrochloride 0.4 mg Capsule
More informationCowen Healthcare Conference
Cowen Healthcare Conference Shire plc March 9, 2010 Michael Cola President, Specialty Pharmaceuticals Our purpose We enable people with life-altering conditions to lead better lives 1 THE SAFE HARBOR STATEMENT
More informationTELECONFERENCE Q August 2015
TELECONFERENCE Q2 2015 19 August 2015 Company disclaimer This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions,
More informationIncrease in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) H revenues and results - 24 July 2014
Increase in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) ( ) H1 2014 revenues and results - 24 July 2014 Forward-looking statement This presentation contains
More informationLombard Medical Technologies
Outlook 8 August 2011 Lombard Medical Technologies Price 0.7p Market cap 28m Year end Revenue ( m) PBT* ( m) EPS* (p) DPS (p) P/E (x) Yield (%) Share price graph 12/09 2.4 (7.8) (0.8) 0.0 N/A N/A 12/10
More informationStraumann s net revenues reach CHF 185 million in Q1, driven by continuing double-digit growth in America
Media release Straumann s net revenues reach CHF 185 million in Q1, driven by continuing double-digit growth in America Group net revenue rises 2% (l.c.) as double-digit increases across America offset
More informationHALOZYME REPORTS SECOND QUARTER 2018 RESULTS
Contacts: Robert H. Uhl Managing Director Westwicke Partners, LLC 858-356-5932 robert.uhl@westwicke.com Laurie Stelzer 858-704-8222 ir@halozyme.com FOR IMMEDIATE RELEASE HALOZYME REPORTS SECOND QUARTER
More informationRight Choice for Right Angles
Right Choice for Right Angles The Anatomy of Technology Aorfix gives you technology that conforms to patient anatomy, optimising both procedure and post-operative performance. Fishmouth for optimum neck
More informationPutting ALK on the right growth trajectory
Putting ALK on the right growth trajectory Økonomisk Ugebrevs Kapitalmarkedseftermiddag 15. marts 2018 Per Plotnikof, VP Corporate Communications and IR Marts 2018 Allergy: a global disease with a large
More informationDiagnostics for the early detection and prevention of colon cancer. Fourth-Quarter 2014 Earnings Call February 24, 2015
Diagnostics for the early detection and prevention of colon cancer Fourth-Quarter 2014 Earnings Call February 24, 2015 Safe Harbor Statement Certain statements made in this presentation contain forward-looking
More informationAnatomy-Driven Endograft Selection for Abdominal Aortic Aneurysm Repair S. Jay Mathews, MD, MS, FACC
Anatomy-Driven Endograft Selection for Abdominal Aortic Aneurysm Repair S. Jay Mathews, MD, MS, FACC Interventional Cardiologist/Endovascular Specialist Bradenton Cardiology Center Bradenton, FL, USA Disclosures
More informationPatrick J. Sullivan Chief Executive Officer. January 9, 2018 Investor Presentation
Patrick J. Sullivan Chief Executive Officer January 9, 2018 Investor Presentation Forward Looking Statement This presentation may contain forward-looking statements concerning Insulet's expectations, anticipations,
More informationAuthors: Jennifer Kates (Kaiser Family Foundation), Eric Lief (The Stimson Center), Carlos Avila (UNAIDS).
Financing the response to AIDS in low- and middleincome countries: International assistance from the G8, European Commission and other donor Governments in 2008 Authors: Jennifer Kates (Kaiser Family Foundation),
More informationIpsen Acquisition of Clementia Pharmaceuticals. February 25, 2019
Ipsen Acquisition of Clementia Pharmaceuticals February 25, 2019 Disclaimer & Safe Harbor This presentation includes only summary information and does not purport to be comprehensive. Forward-looking statements,
More informationCountry Coverage. Company Coverage
Global Heart Valve Devices Market: Analysis By Procedure (Replacement & Repair), Replacement Procedure By Technique (Mechanical, Bioprosthetic & TAVR), Repair Procedure By Technique (Surgical, Balloon
More informationDelivering Innovation. Where It s Needed. August 2018
Delivering Innovation. Where It s Needed. August 2018 Forward-Looking Statements Certain statements in this presentation constitute forward-looking statements within the meaning of the Securities Act of
More informationRevolutionizing how advanced heart disease is treated
LEERINK Partners 5th Annual Healthcare Conference Revolutionizing how advanced heart disease is treated NASDAQ: NCVN, TSX: NVC Alexei Marko, CEO February 2016 Forward-Looking Statements Statements contained
More informationPresentation to 2019 JP Morgan Healthcare Conference
For immediate release 10 January 2019 Presentation to 2019 JP Morgan Healthcare Conference Please find attached CSL Limited s presentation at the 2019 JP Morgan Healthcare Conference. For further information,
More informationGlobal Transcatheter Mitral Valve Repair and Replacement (TMVR) Market: Analysis By Region, By Country: Opportunities and Forecast ( )
Global Transcatheter Mitral Valve Repair and Replacement (TMVR) Market: Analysis By Region, By Country: Opportunities and Forecast (2017-2022) By Region- North America, Europe, APAC and RoW By Country
More informationInternational Operations overview and strategy. Maziar Mike Doustdar EVP International Operations. Slide 1
Slide 1 International Operations overview and strategy Maziar Mike Doustdar EVP International Operations KUALA LUMPUR Home of International Operations Business Area Southeast Asia Slide 2 Forward-looking
More informationLivaNova Investor Day
LivaNova Investor Day TRANSCATHETER MITRAL VALVE REPLACEMENT (TMVR) Paul Buckman General Manager, TMVR September 14, 2017 Safe Harbor Statement Certain statements in this presentation, other than purely
More informationSAMPLE. Sterilization and Disinfectant Equipment Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018
Sterilization and Disinfectant Equipment Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2018 Reference Code: GDME0165BDB Publication Date: January 2013 GlobalData. This report
More informationLEERINK GLOBAL HEALTHCARE CONFERENCE. Marino Garcia EVP, Chief Strategy Officer February 15, 2017
LEERINK GLOBAL HEALTHCARE CONFERENCE Marino Garcia EVP, Chief Strategy Officer February 15, 2017 SAFE HARBOR STATEMENT This presentation and any statements made for and during any presentation or meeting
More informationAviragen Therapeutics, Inc. and Vaxart Inc. Joint Conference Call UNLOCKING THE FULL POTENTIAL OF ORAL VACCINES
Aviragen Therapeutics, Inc. and Vaxart Inc. Joint Conference Call UNLOCKING THE FULL POTENTIAL OF ORAL VACCINES October 30, 2017 Safe Harbor This presentation contains forward-looking statements about
More informationDurable outcomes. Proven performance.
Durable outcomes. Proven performance. GORE EXCLUDER AAA Endoprosthesis GORE EXCLUDER Iliac Branch Endoprosthesis GORE EXCLUDER AAA Endoprosthesis The most-studied* EVAR stent graft designed for durable
More informationENCORE, a Study to Investigate the Durability of Polymer EVAR with Ovation A Contemporary Review of 1296 Patients
ENCORE, a Study to Investigate the Durability of Polymer EVAR with Ovation A Contemporary Review of 1296 Patients The Ovation System is approved to treat infrarenal abdominal aortic aneurysms and is not
More informationJEFFERIES 2016 HEALTHCARE CONFERENCE. June 2016
JEFFERIES 2016 HEALTHCARE CONFERENCE June 2016 Company disclaimer This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions,
More information